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Background.– To estimate the nature and intensity of pain during botulinum
toxin injections in treatment of adult spasticity.
Methods.– Observational study on 46 patients (19M/27W, 60.5 ± 16 years) eva-
luated without analgesia during botulinum toxin type A injections, 6.5 years after
stroke. Pain was evaluated by numeric verbal scale (0–10) after needle insertion,
electric stimulation, toxin injection and needle withdrawal. The needle type was
accounted for. Data is presented in median values [25 and 75th percentiles].
Results.– The most painful time was during stimulation (4 [2.6–5.3]; P < 0.001)
followed by needle insertion (3.1 [1.3–4.1]; P < 0.01). The pain resulting from
toxin injection was not negligible (1 [0.12–2.3]; P < 0.01), superior to the pain
resulting from needle withdrawal (0 [0–0.3]; P < 0.05]. The form of toxin used,
the number of injections and the injected volume per muscle had no influence on
the pain. The intensity of pain resulting from needle insertion and stimulation
was influenced by the length and the diameter of needles.
Conclusions.– The stimulation for muscle identification can be very painful. The
needle choice influences the pain intensity. This data advocates for procedure
adaptation in order to reduce pain.
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Background.– To specify the influence of clinical characteristics of patients on
the pain intensity during botulinum toxin injections in spasticity treatment.
Methods.– Observational study on 46 patients (19M/27W, 60.5 ± 16 years) eva-
luated without analgesia during botulinum toxin type A injections, 6.5 years after
stroke. Pain was evaluated by numeric verbal scale (0–10). The sensory disorders
were evaluated by Semmes–Weinstein monofilaments. The data is presented in
median values [25 and 75th percentiles].
Results.– A total of 1288 numerical verbal scale results were analysed. The
number of injected muscles per patient was 4.3 and the number of injections per
muscle was 1.6. Age, type of stroke, stroke side or delay had no influence on
pain. Pain was higher in patients without or light sensory disorders, distal and
small muscles. Females felt greater pain during stimulation than men.
Conclusions.– Female patients and those with light sensory loss, in whom small
and distal muscles are stimulated, are most likely to experience pain during
botulinum toxin injection sessions. In order to reduce the high risk of pain
among these patients, analgesia is required, as well an adaptation and a learning
of therapeutic techniques.
http://dx.doi.org/10.1016/j.rehab.2014.03.183
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Background.– There is renewed interest in spinal cord stimulation as a treatment
of spasticity. Here, we present documented the positive effects both on spasticity
and on motor control; in a 26-year-old man Strumpell–Lorrain disease with
severe, widespread lower limb spasticity and limitation of mobility.
Methods.– The main parameters tested were: spasticity, gait velocity at self-
preferred and fast speed, time of maintenance right and left unipodal stance.
Measurements were performed stimulation on and off, in many sessions
6 months apart.
Results.– During stimulation, spasticity decreased and postural and gait capa-
cities improved. Gains obtained after 6 months of stimulation were substantial:
11.7% for fast walking, 6.3% for walking at self-preferred speed, 85.5% for the
right unipodal stance and 55% for left unipodal stance. The patient was very
satisfied and reported living normally. This spectacular improvement was even
maintained several hours after the stimulation was stopped.
Conclusions.– This therapeutic approach could be interesting.
http://dx.doi.org/10.1016/j.rehab.2014.03.184
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Background.– Botulinum toxin (BT) is used for dystonia and spasticity in a wide
dose range. The upper end of this range, however, still needs to be explored.
Methods.– In a prospective non-interventional study, we compared a randomly
selected group of dystonia and spasticity patients receiving incobotu-
linumtoxinA (Xeomin®) high dose therapy (HD group, n = 100, single
dose ≥ 400 MU) to a control group receiving Xeomin® regular dose therapy
(RD group, n = 30, single dose ≤ 200 MU).
Results.– HD group patients (56.1 ± 13.8 years, 46 dystonia, 54 spasticity) were
treated with Xeomin® 570.1 ± 158.9 (min 400, max 1200) MU during 10.2 ± 7.0
(min 4, max 37) injection series. HD and RD group patients reported 59 occur-
rences of items on the systemic toxicity questionnaire (STQ). Generalised
weakness, being bed ridden, feeling of residual urine and constipation were
caused by underlying paresis, blurred vision by presbyopia. Dysphagia and dry
eyes were local BT adverse effects. Neurologic examination, serum chemistry
and full blood count did not indicate any systemic adverse effects. No patient
developed antibody induced therapy failure.
Conclusions.– Xeomin® can be used safely in doses ≤ 1200 MU without detec-
table systemic toxicity. This allows expanding the use of BT therapy to patients
with more widespread and more severe muscle hyperactivity conditions.
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Background.– To evaluate through pedobarogramm, the influence of botulinum
toxin type A in gait velocity of post-stroke patients with lower limb spasticity.
Methods.– Seven post-stroke patients with hemiplegia and lower limb spasti-
city were studied. The measurements included: time for the patient to cover
10 m distance; percentage of load in the rear part of the hemiplegic foot during
stance and gait; change in the length of gait after botulinum toxin injection. The
measurements took place before the injection and two weeks and one month
after.
Results.– Gait velocity, magnitude of stride and the load in the rear part of the
foot were improved significantly after the injection of botulinum toxin.
http://dx.doi.org/10.1016/j.rehab.2014.03.186
